The aim of this study was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patients with hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is characterized by cardiomyocyte hypertrophy, myofibrillar disarray, and interstitial fibrosis, resulting in regional and global abnormal generation of contractile force and hindered relaxation (1) . Although the vast majority of patients have normal longevity, progressive and drug-refractory heart failure can develop in others. Given this varied clinical spectrum, symptom assessment and prognostication can be challenging in these patients.
B-type natriuretic peptide (BNP) is a biologically active peptide synthesized and released primarily from cardiac myocytes as a response to neurohormonal activation, myocardial stretch, and wall tension (2) . Circulating plasma BNP levels are elevated in numerous cardiac pathologies in the presence of hemodynamic overload and increased cardiac fibrosis (3) (4) (5) . The use of natriuretic peptides is a wellestablished tool in the diagnosis, prognosis, and management of patients with systolic dysfunction (6, 7) . However, there is a paucity of data on the clinical significance, particularly with regard to survival, of these biomarkers in patients with HCM (8) .
Accordingly, the objective of the present investigation was to determine the prognostic utility of BNP in patients with HCM.
Methods
Patient selection. The study population consisted of 772 patients with HCM evaluated at the Mayo Clinic (Rochester, Minnesota) between January 2006 and May 2009. The diagnosis of HCM was based on the presence of myocardial hypertrophy in the absence of local or systemic etiologies (9, 10) . All patients had a plasma BNP level obtained for clinical purposes at the time of evaluation. Plasma BNP was measured by fluorescence immunoassay (Biosite Diagnostics [now Alere, Inc.], San Diego, California) using a Beckman Coulter DXI 800 instrument. When possible, BNP levels were processed immediately after phlebotomy. Otherwise, samples were spun down and plasma frozen until the sample was analyzed (no more than 3 days). The precision, sensitivity, and stability of this particular BNP assay were previously described (11) . Comprehensive resting 2-dimensional transthoracic echocardiography was performed in all patients, as previously described (12) .
Symptom-limited graded exercise testing was performed using a motor-driven treadmill (Quinton, Seattle, Washington) with an accelerated Naughton protocol. Continuous electrocardiographic monitoring (Marquette Electronics, Milwaukee, Wisconsin) and breath-to-breath metabolic measurement (Medical Graphics, St. Paul, Minnesota) were used, as previously described (13) . All patients provided consent for use of their medical records for research purposes in accordance with Minnesota law and an institutional review board-approved study. Statistical analysis. Continuous variables are expressed as mean AE SD; BNP and left ventricular (LV) outflow tract were not normally distributed and are reported as median with interquartile range. Correlations of continuous variables were examined using Spearman rank correlation coefficients. Comparison of continuous variables was performed using the Wilcoxon rank sum test. Wilcoxon signed rank tests were used for comparison of repeated measures of BNP. For comparisons of contingency variables, the Fisher exact test was used. For multivariate modeling, BNP was transformed using log(BNP). Multivariable linear regression modeling with mixed-direction stepwise selection method (p value threshold to enter ¼ 0.15; to leave, 0.05) was used to determine clinical predictors of log(BNP). Survival free of the study endpoints (all-cause mortality and combined endpoint of mortality and occurrence of septal reduction therapy [SRT]) were assessed using Kaplan-Meier survival curves, with log-rank test p values reported. Cox proportional hazard analysis was performed to determine the relationship of BNP with study endpoints.
Results
Study population. Baseline characteristics of the study population are listed in Tables 1 and 2 . Mean age was 52 AE 16 years (62% male). The vast majority had mild or no symptoms (61% were New York Heart Association [NYHA] functional class I or II). Median BNP for the entire study population was 177.5 (interquartile range [IQR]: 71 to 395) pg/ml. BNP was associated with multiple clinical and echocardiographic parameters, although the correlations with these clinical variables were modest (Spearman r range, À0.02 to 0.45) ( Table 3 ). Multivariate linear regression modeling of log(BNP) (2.2 AE 0.5 log [pg/ ml]) using variables from Table 3 Cardiopulmonary exercise was performed in 429 patients (Table 4) . BNP was related to both peak oxygen consumption (VO 2 ) (Spearman r ¼ À0.44, p < 0.0001) and percent predicted VO 2 achieved during cardiopulmonary exercise testing (Spearman r ¼ À0.33, p < 0.0001). Of 264 patients with mild or no symptoms (NYHA functional class I or II) who underwent exercise testing, the BNP level was Of the 30 deaths, the cause of death was available for 14 (47%). Five of 14 patients died of noncardiac causes, 4 (29%) had sudden cardiac death, 4 (29%) had a cerebrovascular accident, and 1 (7%) died secondary to a heart failure exacerbation. The incidence per 100 person-year follow-up of all-cause mortality was 2.29 (95% CI: 1.47 to 3.52). For the combined endpoint of sudden cardiac death and unknown cause of death, the incidence per 100 personyear follow-up was 1 (Fig. 1C) . Compared with patients in the first tertile, the hazard ratios for death or need for SRT in the second and third tertiles were 2.56 (p ¼ 0.002) and 3.89 (p < 0.0001), respectively. Of note, biomarker ascertainment before and after SRT was performed in 76 patients, with post-procedural BNP assessed 378 days (IQR: 226 to 522 days) after SRT. BNP significantly decreased from 234 pg/ml (IQR: 123 to 507.8 pg/ml) to 151 pg/ml (IQR: 92.3 to 313 pg/ml) in these patients (Wilcoxon p ¼ 0.009).
Discussion
The present investigation is the largest longitudinal study of BNP in patients with HCM. We demonstrate that increases in BNP are associated with adverse survival and a greater need for subsequent SRT. These data demonstrate the potential clinical utility of BNP in HCM and suggest that these biomarkers may be used to help with prognostication of these patients.
Studies of BNP in HCM to date have largely focused on correlation of BNP with echocardiographic parameters or functional class (14) (15) (16) (17) (18) (19) (20) . Our findings (Table 3) corroborate these smaller studies. However, the prognostic impact of BNP on survival in HCM remains poorly studied, likely given mortality rates similar to those of the general U.S. adult population for all causes (1). Our large cohort of patients with HCM shows that BNP is an independent predictor of survival, even in patients without severe obstruction, and allows further prognostication during assessment of patients with HCM.
Studies assessing BNP and cardiopulmonary exercise in HCM have presented mixed results (15, 16, 21, 22) . We present the largest analysis to date of cardiopulmonary exercise data and BNP with HCM and demonstrate significant correlation of both peak VO 2 and the percent (23, 24) . Increases in BNP reflect a common end pathway to fluctuating hemodynamic strain. As such, BNP provides insight into the hemodynamic burden on cardiac chambers and the associated adverse ventricular remodeling. Our data reveal a significant decrease in BNP after surgical relief of obstruction. The impact of this change on long-term prognosis remains unclear and requires further study. Study limitations. The present study is a retrospective analysis, with known inherent limitations, including selection bias. Of note, the majority of the patients were minimally symptomatic or asymptomatic (61% NYHA functional class I or II). Although our study represents the largest longitudinal study of BNP in HCM, the overall mortality rate was only 2.3% per year, and the cause of death could not be determined in a number of patients. Thus, our ability of BNP to predict HCM-related death was limited. Nevertheless, there was a clear relationship between BNP and survival free of all-cause mortality, a hard endpoint in previous HCM publications (25, 26) .
Conclusions
The present investigation provides insight into the clinical applicability of BNP in a large population with HCM. Increases in BNP have the potential to identify poor cardiopulmonary exercise tolerance in minimally symptomatic patients and help to identify nonobstructive patients with higher mortality. Routine assessment of natriuretic Increasing tertiles of B-type natriuretic peptide were associated with higher mortality (log-rank p ¼ 0.002) (A), greater risk of future septal reduction therapy (SRT) (log-rank p ¼ 0.001) (B), and the combined endpoint of death or need for subsequent SRT (log-rank p < 0.0001) (C).
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